T1	55 60	NSCLC
T2	27 53	non-small cell lung cancer
T3	77 88	RAS-pathway
T4	139 144	GATA2
T5	235 260	receptor tyrosine kinases
T6	262 265	RTK
T7	361 367	mutant
T8	348 357	wild-type
T9	395 399	RNAi
T10	472 488	decrease in KRAS
T11	576 588	KRAS-pathway
T12	603 606	PC9
T13	614 625	EGFR mutant
T14	741 761	proteasome machinery
T15	763 777	IL-1-signaling
T16	783 796	Rho-signaling
T17	845 850	TRAF6
T18	872 880	ablation
T19	854 859	mouse
T20	1195 1198	Rho
T21	1221 1232	therapeutic
T22	1283 1293	bortezomib
T23	1298 1305	fasudil
T24	1252 1271	clinically approved
